Neurocrine Biosciences (NBIX) is back in focus after reporting strong first quarter 2026 results, with more than US$800 million in net product sales and growth driven by INGREZZA attracting fresh institutional interest.

Alongside the strong quarter, Neurocrine Biosciences has seen a sharp shift in sentiment, with a 37.41% 90 day share price return and 32.71% 1 year total shareholder return pointing to building momentum as recent clinical milestones and earnings progress filter into expectations.

If Neurocrine Biosciences has caught your eye, it could be a good moment to see what else is happening in healthcare AI and related therapeutics through the 41 healthcare AI stocks.

After a 37.41% move over 90 days and with Neurocrine Biosciences now screening closer to market multiples, the real tension is whether the recent run has absorbed most of the upside or if valuation still leaves meaningful room ahead.

Most Popular Narrative: 8.2% Undervalued

With Neurocrine Biosciences last closing at $177.11 against a narrative fair value of $192.88, the widely followed view points to modest upside supported by stronger earnings assumptions and a slightly lower discount rate.

A broad, late-stage and diversified CNS pipeline, including multiple Phase III programs targeting major depressive disorder and schizophrenia, leverages advances in precision medicine and increases visibility for future earnings, supporting potential future valuation multiple expansion.
Ongoing internal innovation in biologics (such as bispecifics, ADCs, peptides), and a strong preclinical pipeline, allows Neurocrine to capitalize on industry advancements in drug modalities, expanding the addressable market and supporting long-term revenue growth.

Want to see what is backing that higher fair value for Neurocrine Biosciences? The narrative leans on ambitious earnings growth, richer margins and a future valuation multiple that assumes real staying power. Curious which specific revenue path and profitability mix must line up to support that price tag over time?

Result: Fair Value of $192.88 (UNDERVALUED)

However, the bullish Neurocrine Biosciences story still hinges on INGREZZA and CRENESSITY continuing to perform, while pricing pressure and tighter payer controls remain live swing factors.

Another View: What Market Multiples Say About Neurocrine Biosciences

While the narrative fair value suggests Neurocrine Biosciences is about 8.2% undervalued, the current P/E of 26.6x tells a different story, sitting above both the US Biotechs industry at 17.4x and the peer average at 23.5x, but slightly below a fair ratio of 28.1x. Is the stock being priced for perfection, or is it simply reflecting its growth profile?

Next Steps

Given the upbeat tone around Neurocrine Biosciences so far, it makes sense to check the data yourself and move quickly while sentiment is still forming. To see what investors are optimistic about in the current setup, take a closer look at the 3 key rewards.

Looking for more investment ideas beyond Neurocrine Biosciences?

If Neurocrine Biosciences has sharpened your focus, do not stop here. Extend your watchlist with a few targeted stock ideas built from clear, data driven screeners.

• Spot potential value leaders by reviewing companies highlighted in the 44 high quality undervalued stocks before the crowd pays closer attention.
• Strengthen your portfolio’s foundation with businesses from the solid balance sheet and fundamentals stocks screener (47 results) that pair financial resilience with fundamental support.
• Get ahead of the market by scanning the screener containing 19 high quality undiscovered gems that combine quality metrics with relatively limited current attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.